{"disease":{"id":"sporadic-inclusion-body-myositis","name":"sporadic inclusion body myositis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01925209","title":"Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02573467","title":"An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":211,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05046821","title":"Sporadic Inclusion Body Myositis Natural History Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"University of California, Irvine","has_results":false},{"nct_id":"NCT00030212","title":"Immune Abnormalities in Sporadic Inclusion Body Myositis","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT02250443","title":"Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04421677","title":"Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"University of Kansas Medical Center","has_results":false},{"nct_id":"NCT06479863","title":"Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Austin Neuromuscular Center","has_results":false},{"nct_id":"NCT03710941","title":"Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}